CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
Advertisement
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced that the European Patent Office (EPO) has confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection. Following the hearing, the opposition division largely dismissed the opposition originally filed by BioNTech SE in April 2023 challenging the patent’s validity and maintained the patent in amended form.
The ruling represents a major milestone in the ongoing patent dispute between CureVac and BioNTech in Germany, which involves a total of six intellectual property rights. Following the ruling, the Regional Court Düsseldorf will decide whether the patent in its amended form has been infringed. An infringement hearing is scheduled for July 1, 2025. A positive infringement decision would trigger proceedings to assess damages in the same court.
“We welcome the decision of the EPO to uphold EP 3 708 668 B1 and remain confident that the patent is infringed in its amended form. Today’s decision marks an important step on our path that we expect will lead to recognition of CureVac’s major contribution to safe and efficacious COVID-19 vaccines as the earliest pioneer in mRNA technology,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. “This effort is a multi-step process in Europe and the U.S. We remain determined to have our contributions to the field of mRNA technology acknowledged and fairly compensated, and to continue making advances that expand the frontiers of mRNA-based medicines.”
EP 3 708 668 B1 describes a foundational invention of CureVac, called split poly-A tail technology, which enhances medical efficacy by improving expression of the protein encoded on an mRNA construct.
CureVac is represented in Germany by Oliver Jan Jüngst from Bird & Bird LLP and Andreas Graf von Stosch from Graf von Stosch Patentanwaltsgesellschaft and represented in the U.S. by Mark H. Izraelewicz from Marshall, Gerstein & Borun LLP and John M. Erbach from Spotts Fain, PC.
Other news from the department politics & laws
Most read news
More news from our other portals
Last viewed contents
ChatGPT grows insect-toxic genetically engineered plant - Blind spot in the EU draft law on genetic engineering
Commission launches new strategy to make Europe a global leader in life sciences by 2030
CureVac Announces Resolution of Patent Litigation with Pfizer/BioNTech - BioNTech’s acquisition of CureVac will be implemented as planned
Time out: We all need a three-day weekend - Researchers confirm health benefits
Ibidi Awarded With the German bAV Prize 2023
Using AI as an exam tutor - Artificial intelligence is set to help human examinees study more effectively
EXIST start-up grant for virtual reality laboratory training - "Wet-Lab-VR": Virtual reality technology revolutionises training for molecular biology laboratories
2025 Future Insight Prize Awarded to Helmholtz Center’s Magdalena Götz for Breakthroughs in Brain Regeneration
Supervisory Board of Bayer AG extends contract of CEO Bill Anderson - Far-reaching transformation advancing, delivering first signs of success
VTU Group appoints Liam O'Neil as new CEO
Bayer extends partnership with Tsinghua University to accelerate pharmaceutical research in China - Extended collaboration underscores Bayer's commitment and growth strategy in innovation in China and globally
